Rubicon Genomics Enters Cancer Diagnostics Agreement with Agendia

Rubicon Genomics (Ann Arbor, MI, USA) and Agendia (Irvine, California, USA; and Amsterdam, The Netherlands) sign agreement for the use of transplex whole genome RNA-amplification technology with Agendia’s Symphony suite of cancer diagnostics. Financial details of the agreement were not disclosed.

This is the first commercial clinical application for Rubicon’s transplex technology that facilitates RNA analysis from formalin-fixed, paraffin-embedded (FFPE) tissue samples. Agendia will incorporate Rubicon’s Transplex kits into the analysis of FFPE patient samples for use with its Symphony suite of breast cancer diagnostics

RNA or DNA extracted from FFPE samples is highly fragmented and it often contains only small amounts of usable DNA or RNA, which might be insufficient for analysis. Rubicon’s Transplex genomic RNA amplification kits and Genomeplex genomic DNA amplification kits are members of Rubicon’s Omniplex family of technologies that are designed and validated to overcome these problems and deliver sufficient quantities of high quality nucleic acids to enable accurate and consistent analyses.

“Rubicon’s Transplex RNA amplification technology for FFPE samples was a standout in our evaluation of the available options for use with our Symphony products for the diagnosis and management of breast cancer,” commented David Macdonald, CEO of Agendia. “Transplex offers product performance and workflow advantages, producing superior results while taking less time. In line with our commitment to ongoing innovation and product excellence, we look forward to incorporating this superior technology into our ongoing diagnostic operations.”

Rubicon’s Omniplex amplification kits use proprietary methods for advanced library synthesis and high-yield amplification to prepare samples for sensitive and accurate polymerase chain reaction (PCR), microarray, and next-generation sequencing analysis for use in clinical medicine and biomedical research. The Omniplex kits are also fast, simple, and amenable to automation.

Rubicon Genomics, Inc. develops and commercializes sample-specific pre-analytical processes to improve the performance and capabilities of DNA and RNA analytical platforms for a variety of clinical testing and research applications.

Agendia is a molecular diagnostics company that develops and markets genomic-based products. Agendia’s Symphony suite of breast cancer products is based on the analysis of hundreds of genes in a patient’s tumor and provides biological insight to address complex treatment decisions.

Related Links:
Rubicon Genomics
Agendia